0.22
-20.71%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Magle Chemoswed Holding
Its shares trade on Nasdaq Stockholm under the ticker MAGLE.ST. It has been listed since 30 June 2020. In the fiscal year to 31 December 2025, it reported revenue of SEK 282.9m and a net loss of SEK 159.9m. At that date it held total assets of SEK 911.0m and shareholders' equity of SEK 395.8m.
Magle Chemoswed Holding AB engages in the provision of contract development and manufacturing services to the pharmaceutical and medical device industry. The company is headquartered in Malmo, Skane. The company went IPO on 2020-06-30. The firm's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 30 Jun 2020
Leadership
Pay as last reported
- Simon MårtenssonDirector, since 2019
- Malin Malmsjö, MD, PhDDirector, since 2016
- Justin Pierce, PhDChief Executive Officer, since 2015
- Fredrik AnderssonChief Operations Officer, since 1999
- Petra SjölinChief Financial Officer, since 2020
- Peter Schuisky, PhDChief Scientific Officer, since 2012
- Hans Henrik Lidgard, LLDChairman, since 2013
- Ingela Fritzon, PhDDirector, since 2019
- Mats Gunnar PetterssonDirector, since 2016
- Sven-Christer NilssonIndependent Director, since 2016
- Joel Magnus EklundDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Provides contract development and manufacturing services for pharmaceutical and medical device industries.
- Operates through subsidiaries Magle Chemoswed AB and Adroit Science AB.
- Focuses on process development and manufacturing of Active Pharmaceutical Ingredients (API).
Weaknesses
- No specific weaknesses mentioned in the provided information.
- Operations are mainly conducted through subsidiaries, which may indicate dependency.
- No details on financial performance or market share provided.
Opportunities
- Growth potential in the pharmaceutical and medical device industries.
- Expansion in areas of wound care and diagnostics with degradable starch microspheres.
- Consultancy services in material characterization and solid phase analysis for pharmaceutical companies.
Threats
- No specific threats mentioned in the provided information.
- Dependence on subsidiaries for operations may pose risks.
- Untrusted source description may lead to inaccurate information.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.